New AMR Report Is ‘A Wake-Up Call’, Says Industry Body
Low Investment, Lack Of Incentives Seen As Key Problems
Executive Summary
Another day, another report on how to tackle the ever-present problem of antimicrobial resistance and the dearth of new treatment. In its latest assessment of the state of play, the AMR Industry Alliance has come up with some alarming facts and figures – and some ideas for the next steps.
You may also be interested in...
Big Pharma’s $1Bn Antibiotic Development Fund Offers ‘Breathing Room’ For Reimbursement Fix
Companies developing antibiotics to get financial and technical support from more than 20 firms contributing to new AMR Action Fund. Initiative is also pushing for reimbursement reform and other policies to support commercial marketing.
Big Pharma’s $1Bn Antibiotic Development Fund Offers ‘Breathing Room’ For Reimbursement Fix
Companies developing antibiotics to get financial and technical support from more than 20 firms contributing to new AMR Action Fund. Initiative is also pushing for reimbursement reform and other policies to support commercial marketing.
Sweden Urges Pharma To Engage In AMR Initiative
Sweden is testing ‘pull incentives’ in hopes of finding viable reward mechanisms that would ensure adequate access to important antibiotics to meet the Scandinavian country’s domestic internal needs.